Elsevier

Vaccine

Volume 32, Issue 22, 7 May 2014, Pages 2623-2630
Vaccine

A multi-stage malaria vaccine candidate targeting both transmission and asexual parasite life-cycle stages

https://doi.org/10.1016/j.vaccine.2014.03.020Get rights and content

Highlights

  • Multi-stage chimera consisting of transmission and asexual blood-stage antigens.

  • This chimera consist of P. falciparum GLURP genetically fused to Pfs48/45.

  • The GLURP-Pfs48/45 chimera elicit bifunctional antibodies in small rodents.

  • The transmission blocking activity is associated with specific IgG levels.

  • The antisera also inhibit asexual blood-stage multiplication in vitro.

Abstract

Effective control and eventual eradication of malaria drives the imperative need for clinical development of a malaria vaccine. Asexual parasite forms are responsible for clinical disease and death while apathogenic gametocytes are responsible for transmission from man to mosquito. Vaccines that combine antigens from both stages may provide direct protection and indirect benefit by reducing the force of infection. We constructed a chimeric antigen composed of a fragment of the Plasmodium falciparum (Pf) glutamate-rich protein fused in frame to a correctly folded fragment of Pfs48/45. The chimera was produced in Lactococcus lactis and induced robust antibody responses in rodents to the individual components. Specific antibodies showed strong transmission blocking activity against multiple Pf-strains in the standard membrane feeding assay and functional activity against asexual stages in the antibody dependent cellular inhibition assay. The combined data provide a strong rationale for entering the next phase of clinical grade production and testing.

Introduction

Considerable reductions in the burden of malaria have been observed in the last decade in association with up-scaling of malaria control efforts. It is, however, acknowledged that further up-scaling with currently available tools are unlikely to result in malaria elimination in the majority of African settings [1]. Novel tools that specifically reduce the transmission of malaria from man to mosquito are needed for this purpose [2]. A vaccine that targets sexual and/or sporogonic development would be of great value for malaria elimination strategies. Classical transmission-blocking malaria vaccines (TBMV), however, do not provide direct protection against clinical disease caused by pathogenic asexual stages. Clinical development of a multi-stage chimeric vaccine incorporating both sexual and asexual blood-stage components inducing functional antibody responses, can address this limitation providing both direct personal protection and delayed benefit by reducing transmission and risk for new infections.

The sexual stage Pfs48/45 antigen is a well-established lead TBMV candidate because of its critical role in parasite fertilisation [3], [4]. Series of monoclonal antibodies (mAbs) have been generated [5] against distinct B-cell epitopes with the capacity to completely block the generation of infected mosquitoes when tested in the standard membrane feeding assay (SMFA). Pfs48/45 is a cysteine-rich protein with multiple disulfide bonds and most transmission blocking B-cell epitopes depend on tertiary structures [6]. Since Pfs48/45 is expressed in gametocytes once the parasite undergoes sexual differentiation in the human host [7], [8], naturally acquired anti-Pfs48/45 antibodies are found in sera from endemic populations, and presence of these antibodies is associated with transmission blocking activity [6], [9], [10], [11]. Although attractive from this perspective for clinical vaccine development, Pfs48/45 has proven to be a difficult target for production in most heterologous expression systems [3], [4], [12], [13], [14], [15], [16], [17].

The asexual blood-stage antigen Glutamate-rich Protein (GLURP) has been identified as a target of naturally acquired immunity against malaria [18], [19], [20]. Results from epidemiological studies show strong correlation between the presence of cytophilic anti-GLURP antibodies and protection against clinical malaria [20]. IgG preparations derived from endemic sera and from volunteers participating in a phase-1 GLURP vaccine trial have been shown to functionally inhibit parasite growth in vitro in co-operation with monocytes [19], [21], [22], [23]. Finally, GLURP is part of the GMZ2 vaccine which is an asexual hybrid protein currently tested in a multicentre phase IIb trial in Africa. It has been relatively easy to produce GLURP in recombinant form [24], [25] and especially food grade Lactococcus lactis has been an ideal expression system [24], most likely because L. lactis exhibits similar codon bias as Plasmodia and therefore does not require codon optimisation or harmonisation prior to heterologous expression [26].

Here, we have produced a correctly-folded functional fragment of Pfs48/45 (10C) as a chimeric antigen fused in frame with a section of GLURP (GLURP.RO) in L. lactis. Purified R0.10C induced functional antibodies in rats showing both TB activity and asexual growth inhibition against a panel of Pf strains of different geographical origin.

Section snippets

Construction of plasmid and growth conditions

pLEA5: glurp79-1500 fragment (Genbank M59706) was amplified from F32 gDNA with the primers 5′-CCAGATCTACAAGTGAGAATAGAAATAAACGAATC (GA52) and 5′-CTATACTTGATATAACCTTTTCAGTATTATCTGCTTCATGCTCGCTTTTTTCCGATTC (GA4), and the pfs48/45475-1284 fragment (corresponding to bp 475–1282 of Genbank: NC_004331.2) was amplified from 3D7 gDNA using the primers 5′-GAATCGGAAAAAAGCGAGCATGAAGCAGATAATACTGAAAAGGTTATATCAAGTATAG (GA12) and 5′-CCAGATCTCTAATGGTGATGATGGTGATGTGCTGAATCTATAGTAACTGTCATATAAG (GA53). The GA53

Expression, purification and characterisation of monomeric R0.10C

Development of a Pfs48/45-based subunit vaccine has been a formidable task because correct folding of TB epitopes is essential for its capacity to elicit functional antibodies [4]. Here, we have used a set of TB mAbs to guide the expression of correctly folded Pfs48/45. A Chimeric protein (R0.10C) was generated between the N-terminal part of GLURP (R0) and the C-terminal part of Pfs48/45 (10C) (Fig. 1A). The corresponding plasmid, pLEA5, was transformed into L. lactis MG1363 resulting in clonal

Discussion

The multi-stage life cycle of Pf with distinct antigenic composition and function provides the opportunity to simultaneously target both sexual and asexual blood stages for vaccine development purposes. In this study a multi-stage chimera was generated containing the blood-stage vaccine candidate GLURP.R0 fused in frame to C-terminal 10-cysteine (10C) fragment of sexual-stage protein Pfs48/45. For the latter we focussed on conformational epitope I, a major target for TB antibodies [30].

Conflicts of Interests

The authors report no conflicts of interests.

Acknowledgements

This work was supported by Seventh Framework Program Theme Health-2009-2.3.2-5, Grant 242079, and Proof of Concept funding, Ministry of Science, Innovation and Higher Education, Denmark. The authors would like to thank Dr. Tom Churcher (Imperial College, London, UK) for support in data analysis, Tenna Jensen for technical assistance.

References (47)

  • N. Outchkourov et al.

    Epitope analysis of the malaria surface antigen pfs48/45 identifies a subdomain that elicits transmission blocking antibodies

    J Biol Chem

    (2007)
  • A. Lensen et al.

    Measurement by membrane feeding of reduction in Plasmodium falciparum transmission induced by endemic sera

    Trans R Soc Trop Med Hyg

    (1996)
  • T.A. Smith et al.

    Uses of mosquito-stage transmission-blocking vaccines against Plasmodium falciparum

    Trends Parasitol

    (2011)
  • T.S. Churcher et al.

    Measuring the blockade of malaria transmission—an analysis of the Standard Membrane Feeding Assay

    Int J Parasitol

    (2012)
  • T.G. Anthony et al.

    Evidence of non-neutral polymorphism in Plasmodium falciparum gamete surface protein genes Pfs47 and Pfs48/45

    Mol Biochem Parasitol

    (2007)
  • K. Stricker et al.

    Conservation and heterogeneity of the Glutamate-rich protein (GLURP) among field isolates and laboratory lines of Plasmodium falciparum

    Mol Biochem Parasitol

    (2000)
  • W. Roeffen et al.

    Plasmodium falciparum: production and characterization of rat monoclonal antibodies specific for the sexual-stage Pfs48/45 antigen

    Exp Parasitol

    (2001)
  • J.T. Griffin et al.

    Reducing Plasmodium falciparum malaria transmission in Africa: a model-based evaluation of intervention strategies

    PLoS Med

    (2010)
  • P.L. Alonso et al.

    A research agenda to underpin malaria eradication

    PLoS Med

    (2011)
  • D.R. Chowdhury et al.

    A potent malaria transmission blocking vaccine based on codon harmonized full length Pfs48/45 expressed in Escherichia coli

    PLoS One

    (2009)
  • N.S. Outchkourov et al.

    Correctly folded Pfs48/45 protein of Plasmodium falciparum elicits malaria transmission-blocking immunity in mice

    Proc Natl Acad Sci U S A

    (2008)
  • T. Bousema et al.

    Epidemiology and infectivity of Plasmodium falciparum and Plasmodium vivax gametocytes in relation to malaria control and elimination

    Clinical Microbiology Reviews

    (2011)
  • W. Roeffen et al.

    A comparison of transmission-blocking activity with reactivity in a Plasmodium falciparum 48/45-kD molecule-specific competition enzyme-linked immunosorbent assay

    Am J Trop Med Hyg

    (1995)
  • Cited by (80)

    View all citing articles on Scopus
    View full text